SCHEMBL7981635

SCHEMBL7981635

COC(=O)c1ccn2c(C(=O)/C=C/N(C)C)c(C)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
LMNA P02545 7/20 0.43
RAB9A P51151 6/20 0.43
NPC1 O15118 4/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.41
HTT P42858 4/20 0.41
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 6/20 0.39
HSD17B10 Q99714 1/20 0.39
HPGD P15428 1/20 0.39
GAA P10253 2/20 0.38
MITF O75030 1/20 0.37
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7964745 0.84 MAPT (0.52) MAPTLMNARAB9ANPC1NPSR1
SCHEMBL7976305 0.83 KMT2A (0.50) MAPTLMNARAB9ANPC1NPSR1
SCHEMBL7976885 0.81 MAPT (0.46) MAPTLMNARAB9ANPC1NPSR1
SCHEMBL7981619 0.80 KMT2A (0.55) MAPTRAB9ANPC1SMN1; SMN2HTT
SCHEMBL7964747 0.77 LMNA (0.65) MAPTLMNARAB9ANPC1NPSR1
SCHEMBL976070 0.76 KDM4E (0.48) MAPTLMNARAB9ASMN1; SMN2HTT
SCHEMBL7976791 0.73 LMNA (0.53) MAPTLMNARAB9ANPC1NPSR1
SCHEMBL7965462 0.70 LMNA (0.44) MAPTLMNARAB9ANPC1NPSR1
SCHEMBL4256806 0.69 MAPT (0.63) MAPTLMNARAB9ANPC1SMN1; SMN2
SCHEMBL4256808 0.69 MAPT (0.63) MAPTLMNARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 MAPT 2011/4885LMNA 1714/4885RAB9A 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.